Last reviewed · How we verify

Hospira, now a wholly owned subsidiary of Pfizer — Portfolio Competitive Intelligence Brief

Hospira, now a wholly owned subsidiary of Pfizer pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
DA-9501 DA-9501 phase 3 Herbal extract / Hepatoprotective agent Hepatology / Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hoffmann-La Roche · 1 shared drug class
  2. Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 shared drug class
  3. Life Extension Foundation Inc. · 1 shared drug class
  4. Remedor Biomed Ltd · 1 shared drug class
  5. Seoul National University Hospital · 1 shared drug class
  6. University Hospital, Brest · 1 shared drug class
  7. VA Office of Research and Development · 1 shared drug class
  8. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hospira, now a wholly owned subsidiary of Pfizer:

Cite this brief

Drug Landscape (2026). Hospira, now a wholly owned subsidiary of Pfizer — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hospira-now-a-wholly-owned-subsidiary-of-pfizer. Accessed 2026-05-17.

Related